TEVA Q4 2018 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.6B-16.5% YoY

Gross Profit

$2.0B43.2% margin

Operating Income

-$3.2B-69.4% margin

Net Income

-$2.9B-63.3% margin

EPS (Diluted)

$-2.80

QoQ Revenue Growth

+0.7%

Cash Flow

Operating Cash Flow

$367M

Free Cash Flow

$154M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$60.7B

Total Liabilities

$44.9B

Stockholders' Equity

$14.7B

Cash & Equivalents

$1.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.6B	$5.5B	-16.5%
Gross Profit	$2.0B	$2.5B	-22.5%
Operating Income	-$3.2B	-$13.0B	+75.7%
Net Income	-$2.9B	-$11.5B	+75.0%

Revenue Segments

International Markets

$740M66%

Other Activities

$377M34%

Geographic Segments

North America

$1.9B61%

Europe

$1.2B39%